首页>
外国专利>
Non-native glucagon peptides with enhanced activity at the glp-1 receptor and pharmaceutical compositions comprising the same
Non-native glucagon peptides with enhanced activity at the glp-1 receptor and pharmaceutical compositions comprising the same
展开▼
机译:对glp-1受体具有增强活性的非天然胰高血糖素肽和包含该肽的药物组合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. These modified glucagon co-agonist analogs may be combined with other anti-diabetic or anti-obesity compounds and used to control hyperglycemia, or to induce weight loss or prevent weight gain. In one embodiment the modified glucagon peptides comprise lactam bridges or substitution of the terminal carboxylic acid with an amide group. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR). Use of a glucagon/GLP-1 co-agonist for administration in combination with an anti-diabetic agent or anti-obesity agent.
展开▼
机译:公开了相对于天然胰高血糖素,在胰高血糖素受体上具有增强的效力的修饰的胰高血糖素肽。这些修饰的胰高血糖素共激动剂类似物可以与其他抗糖尿病或抗肥胖化合物组合,并用于控制高血糖症,或引起体重减轻或防止体重增加。在一个实施方案中,修饰的胰高血糖素肽包含内酰胺桥或末端羧酸被酰胺基取代。这些高效能胰高血糖素类似物的溶解性和稳定性可以通过聚乙二醇化,羧基末端氨基酸取代或添加选自SEQ ID NO:26(GPSSGAPPPS)的羧基末端肽修饰多肽来进一步提高),SEQ ID NO:27(KRNRNNIA)和SEQ ID NO:28(KRNR)。胰高血糖素/ GLP-1共激动剂与抗糖尿病药或抗肥胖药联合给药的用途。
展开▼